Kala Study for Persistent Corneal Epithelial Defect

Trial ID:
Peter Krall, MD
The purpose of this study is to evaluate the safety and effectiveness of two doses (low and high) of the investigational KPI-012 eye drop for the treatment of persistent corneal epithelial defects (PCED). PCED is a wound on the front surface of the eye (cornea) that is not healing.

Inclusion Criteria

Patients must:
  • Be 18 or older.
  • Have medically documented PCED.
  • Be willing to stop current medications.

Exclusion Criteria

Patients must not:
  • Use any other eye medications other than the study eye drops.
  • Have used Oxervate within 30 days.
  • Have had any surgical procedures for PCED.

Additional Info

  • Participants will be randomized (like the flip of a coin) to the study eye drops or placebo eye drops (no active ingredient).
  • An antibiotic eyedrop and artificial tear eyedrop will be provided by the study in addition to the study eyedrop.
  • Search NCT 05727878 at https://clinicaltrials.gov website for more information.

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org